iTeos Therapeutics (NASDAQ:ITOS) Price Target Increased to $46.00 by Analysts at HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) had its price target boosted by analysts at HC Wainwright from $44.00 to $46.00 in a research report issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 170.27% from the company's previous close.

Separately, Wedbush restated an "outperform" rating and set a $18.00 target price (down previously from $25.00) on shares of iTeos Therapeutics in a research report on Wednesday, March 6th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS traded down $0.42 during trading hours on Monday, reaching $17.02. The stock had a trading volume of 1,501,016 shares, compared to its average volume of 338,107. iTeos Therapeutics has a twelve month low of $8.20 and a twelve month high of $18.75. The business's fifty day moving average is $11.79 and its two-hundred day moving average is $10.86. The company has a market cap of $612.21 million, a price-to-earnings ratio of -4.61 and a beta of 1.27.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.18. Sell-side analysts forecast that iTeos Therapeutics will post -4.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in shares of iTeos Therapeutics by 131.5% in the third quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company's stock valued at $25,000 after acquiring an additional 1,299 shares during the last quarter. Federated Hermes Inc. raised its position in iTeos Therapeutics by 4,648.4% in the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company's stock valued at $32,000 after purchasing an additional 2,882 shares during the last quarter. Gladius Capital Management LP boosted its stake in iTeos Therapeutics by 48.7% in the fourth quarter. Gladius Capital Management LP now owns 3,131 shares of the company's stock worth $34,000 after purchasing an additional 1,026 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of iTeos Therapeutics by 348.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company's stock worth $45,000 after purchasing an additional 3,216 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of iTeos Therapeutics by 268.5% in the fourth quarter. Signaturefd LLC now owns 4,481 shares of the company's stock valued at $49,000 after buying an additional 3,265 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.